Production and Characterization of Monoclonal Antibodies Specific for a Conserved Epitope within Hepatitis C Virus Hypervariable Region 1
Open Access
- 15 December 2001
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 75 (24) , 12412-12420
- https://doi.org/10.1128/jvi.75.24.12412-12420.2001
Abstract
Frequent mutations in hypervariable region 1 (HVR1) of the main envelope protein of hepatitis C virus (HCV) is a major mechanism of persistence by escaping the host immune recognition. HVR1 contains an epitope eliciting neutralizing antibodies. This study was aimed to prepare broadly cross-reacting, high-affinity, monoclonal antibodies (MAb) to the HVR1 C terminus of HCV with potential therapeutic neutralizing capacity. A conserved amino residue group of glycine (G) at position 23 and glutamic acid (Q) at position 26 in HVR1 was confirmed as a key epitope against which two MAbs were selected and characterized. MAbs 2P24 and 15H4 were immunoglobulin G1 kappa chain [IgG1(κ)], cross-reacted with 32 and 30 of 39 random C-terminal HVR1 peptides, respectively, and did not react with other HCV peptides. The V H of 2P24 and 15H4 heavy chains originated from Igh germ line v gene family 1 and 8, respectively. In contrast, the V L κ sequences were highly homologous. The affinity ( K d ) of 2P24 and 15H4 (10 −9 or 10 −8 M with two immunizing peptides and 10 −8 M with two nonimmunizing HVR1 peptides) paralleled the reactivity obtained with peptide enzyme immunoassay. MAbs 2P24 and 15H4 captured 25 of 31 (81%) HCV in unselected patients' plasmas. These antibodies also blocked HCV binding to Molt-4 cells in a dose-dependent fashion. The data presented suggest that broadly cross-reactive MAbs to a conserved epitope within HCV HVR1 can be produced. Clinical application for passive immunization in HCV-related chronic liver disease and after liver transplantation is considered.Keywords
This publication has 50 references indexed in Scilit:
- Antigenicity and Immunogenicity of Novel Chimeric Hepatitis B Surface Antigen Particles with Exposed Hepatitis C Virus EpitopesJournal of Virology, 2001
- European collaborative study on factors influencing outcome after liver transplantation for hepatitis CGastroenterology, 1999
- Antibody responses to hepatitis C virus hypervariable region 1: Evidence for cross-reactivity and immune-mediated sequence variationHepatology, 1999
- Human recombinant single‐chain antibody fragments, specific for the hypervariable region 1 of hepatitis C virus, from immune phage‐display librariesJournal of Viral Hepatitis, 1999
- High Incidence of Allograft Cirrhosis in Hepatitis C Virus Genotype 1B Infection Following Transplantation: Relationship With Rejection EpisodesHepatology, 1999
- The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantationHepatology, 1998
- Morbidity and mortality of recurrent hepatitis C infection after orthotopic liver transplantationJournal of Viral Hepatitis, 1997
- The impact of hepatitis C virus infection on renal allograft recipientsKidney International, 1994
- HEPATITIS C IS A POOR PROGNOSTIC INDICATOR IN BLACK KIDNEY TRANSPLANT RECIPIENTSTransplantation, 1993
- Isolation of a cDNA cLone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis GenomeScience, 1989